Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. (Nasdaq: KTTA, KTTAW) generates frequent news as a clinical-stage biotechnology company centered on PAS-004, a next-generation macrocyclic oral MEK inhibitor. Coverage of KTTA and KTTAW news often focuses on clinical trial progress in neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), MAPK pathway-driven advanced cancers and ALS, as well as capital markets and regulatory developments that shape the company’s trajectory.
Investors following Pasithea’s news can expect detailed updates on its Phase 1 and Phase 1/1b studies, including safety, pharmacokinetic and pharmacodynamic data, dose-escalation decisions, and early signs of clinical activity such as partial responses or disease control rates in advanced cancer patients. The company also reports on the activation of new clinical trial sites in regions such as the United States, South Korea and Australia for NF1-PN, and on grant-funded initiatives like the Hoffman ALS Clinical Trial Award supporting a Phase 1 PAS-004 study in ALS patients.
Beyond clinical results, Pasithea news includes financing events such as public offerings of common stock and at-the-market programs, with stated uses of proceeds for research, clinical trials, technology development, licensing and potential acquisitions. Regulatory and governance items disclosed through press releases and SEC filings, including proxy proposals, stock incentive plan amendments and responses to Nasdaq listing notices, also feature in the news flow.
For readers tracking KTTA and KTTAW, this news stream offers insight into how Pasithea advances PAS-004 across NF1-PN, oncology and ALS, how it manages its capital structure, and how regulatory milestones may influence its development plans. Regularly reviewing these updates can help contextualize the company’s clinical data, trial timelines and corporate actions over time.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has reached a Settlement and Cooperation Agreement with the Camac Group, resolving all litigation issues. The Camac Group will observe a three-year standstill and has agreed to sell 3,205,282 shares of common stock at $1.0003 each, reflecting the five-day average price. Pasithea will also reimburse certain expenses. CEO Tiago Reis Marques expressed optimism about this agreement, stating it allows the company to focus on advancing its CNS therapies. The Board of Directors will continue overseeing the company's strategy following a recent Special Meeting.
Pasithea Therapeutics (NASDAQ: KTTA) has announced its preclinical data for PAS-003, a monoclonal antibody targeting Alpha 5 Beta 1 integrin as a potential treatment for amyotrophic lateral sclerosis (ALS) and related CNS disorders. The presentation will occur on December 7th at the Antibody Engineering & Therapeutics Conference in San Diego, by Dr. Lawrence Steinman, Chairman of Pasithea. PAS-003 has demonstrated significant improvements in SOD1 mouse models, indicating its promise in improving clinical outcomes for ALS patients.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has postponed its Special Stockholder Meeting from November 29, 2022, to December 9, 2022, at 9:00 am ET. This decision allows more time for stockholder voting proxies. The meeting will still address the proposals submitted by a Dissident Group, which includes several investment firms and individuals. The record date remains November 9, 2022. Pasithea is focused on innovative treatments for CNS disorders, including ALS and Multiple Sclerosis, leveraging its expertise in neuroscience.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will present results from a preclinical study on their tolerizing vaccine PAS002 for multiple sclerosis at the Immunotherapy 2022 Symposium in Buenos Aires from Oct. 14-17, 2022. Prof. Steinman and Nobel laureate Dr. James Allison will receive honorary doctorates from the University of Buenos Aires. CEO Dr. Tiago Reis Marques expressed excitement about sharing their findings and their commitment to developing effective neurological treatments.
Pasithea Therapeutics has acquired AlloMek Therapeutics for $1.05 million in cash, 2.7 million shares, and warrants for an additional 1 million shares. The acquisition aims to enhance Pasithea's CNS product portfolio with CIP-137401, a next-generation MEK inhibitor designed for treating neurofibromatosis type 1 (NF1) and Noonan syndrome. The FDA has granted orphan-drug designation for CIP-137401. An IND application is expected to be filed in the second half of 2023, followed by Phase 1 trials. The acquisition supports long-term growth and potential synergies with existing programs.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced that the Camac Group has met the criteria to call a Special Meeting of Stockholders as of September 28, 2022. The company clarifies that previous notifications from the group were invalid. No action is required from stockholders at this time. In its first year, Pasithea has made significant progress in drug development for CNS disorders, achieving positive preclinical results and expanding its scientific team. Further details about the Special Meeting will be provided soon.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has appointed Alfred J. Novak to its Board of Directors, replacing Dr. Yassine Bendiabdallah, who stepped down on September 14, 2022. Mr. Novak brings over 30 years of experience in life sciences, with a history of significant financial transactions and successful exits, including Dova Pharmaceuticals and Biosense. Chairman Lawrence Steinman expressed enthusiasm for Mr. Novak's contributions toward advancing Pasithea's drug candidates. The company specializes in developing treatments for CNS disorders and providing ketamine infusion services.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has appointed Dr. Merit Cudkowicz to its Scientific Advisory Board, bringing extensive expertise in ALS and neurological diseases. Dr. Cudkowicz, Chief of Neurology at Massachusetts General Hospital, has significantly advanced ALS research and clinical trials. Her collaboration is expected to enhance Pasithea's development of its monoclonal antibody targeting alpha-5/beta-1 integrin, which shows promising preclinical efficacy. Dr. Cudkowicz’s insights are poised to drive innovation in treatment approaches for ALS.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced that CEO Dr. Tiago Reis Marques will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation is scheduled for September 12, 2022, at 7:00 AM ET. Attendees can request virtual one-on-one meetings through H.C. Wainwright. A pre-recorded presentation will also be available on the Company’s website. Pasithea focuses on researching treatments for psychiatric and neurological disorders, including IV ketamine infusions for patients in clinical and home settings.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) will present preclinical results of its DNA vaccine, PAS002, targeting multiple sclerosis at the conference 'From Laboratory to Clinic: Medicine after COVID' on August 30, 2022, at Trinity College, Oxford University. The conference, established in 1984, unites researchers to share advancements in immunology and molecular medicine. CEO Dr. Tiago Reis Marques expressed optimism about the findings contributing to new treatments for neurological disorders. The keynote will be delivered by Professor Lawrence Steinman, along with other leading experts in the field.
FAQ
What is the current stock price of Pasithea Therapeutics (KTTAW)?
